![](https://endpts.com/wp-content/uploads/2020/07/36C4CF2A-D24D-448D-86A5-7EAE2A4C14B9-scaled.jpeg)
Richard DiMarchi, MBX Biosciences
Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease
A scientist-executive team that, over the last decade, sold one diabetes biotech to Roche for up-to $537 million and two others to Novo Nordisk for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.